Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label Phase 3 Study of APG-157 as Neoadjuvant Therapy or as Induction and Maintenance Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07667296 is registered in ClinicalTrials.gov with Aveta Biomics, Inc. as lead sponsor.

NCT NCT07667296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07667296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label Phase 3 Study of APG-157 as Neoadjuvant Therapy or as Induction and Maintenance Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Lead sponsor
Aveta Biomics, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
December 31, 2032
Enrollment
826 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck (hnscc), head and neck cancer, oral cavity, oral cavity carcinoma, oral cavity squamous cell carcinoma, oropharyngeal, oropharynx squamous cell carcinoma